Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Tianjin Medical University Cancer Institute and Hospital: Clinical Trials & FDA Approval Profile

Tianjin Medical University Cancer Institute and Hospital (Global / Institutional) sponsors 273 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 158 active protocols (73 recruiting now), 11 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.7%
Median Closed Enrollment vs National (145 pts)36 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Tianjin Medical University Cancer Institute and Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)273
Active Pipeline (Recruiting Now)158 (73)
Completed vs Stopped Early11 / 2 (0.7%)
Median Closed Actual Enrollment36 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Tianjin Medical University Cancer Institute and Hospital
Hospital Research SiteLocationShared Protocols
Tianjin Medical University Cancer Institute and HospitalTianjin95
Tianjin Medical University Cancer Institute & HospitalTianjin, Tianjin Municipality40
Tianjin Cancer HospitalTianjin12

Explore interactive annual charts and M&A subsidiary rollups in the Tianjin Medical University Cancer Institute and Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI